Alpha Tau Medical

Alpha Tau Medical The Alpha DaRT technology was developed in 2003 at Tel Aviv University. The findings were published in 12 papers in peer-reviewed scientific journals.

Alpha Tau Medical (https://www.alphatau.com/) focuses on research, development and commercialization of Alpha DaRT (Diffusing Alpha-Emitters Radiation Therapy) for the treatment of solid cancer tumors. Alpha Tau Medical is an Israeli medical device company that focuses on research, development, and commercialization of Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) for the treatment of so

lid cancer. Since then, numerous preclinical trials have found the technology to be effective and safe for various indications and anatomic areas. Today, the company is running its first clinical trial with very promising preliminary results.

Alpha Tau Medical and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Pa...
03/06/2026

Alpha Tau Medical and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients

🔵 Joint partnership leverages Alpha Tau’s highly potent, localized alpha-radiation technology and Tolmar’s commercial leadership to transform the U.S. uro-oncology landscape

🔵 Collaboration elevates prostate cancer as a core strategic focus, backed by Tolmar’s initial $15M manufacturing investment, $20M equity infusion at $11.99 per share (25% premium to 30-day VWAP), and up to $161.5M in clinical, regulatory and commercial milestones for the first indication

🔵 Agreement grants Tolmar exclusive U.S. commercialization rights for prostate cancer, with an option to expand into bladder cancer subject to additional payments

🔵 Alpha Tau to manufacture Alpha DaRT for Tolmar’s commercialization, to be sold to Tolmar at 60% of the onward net sales price, subject to certain adjustments

For full PR - Check the first comment

Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT Pancreatic Cancer Studies Presented at 2026 America...
01/06/2026

Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT Pancreatic Cancer Studies Presented at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

✅ Results reinforce the potential feasibility and safety of Alpha DaRT as a one-time, minimally invasive intratumoral treatment that fits naturally into the patient journey

✅ Pooled analysis of three prospective Phase I/II studies in locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) demonstrates encouraging median overall survival (mOS) across chemotherapy-naive, second-line, and heavily pretreated patient populations

✅ Patients treated with Alpha DaRT after 1st line chemotherapy reached median overall survival (mOS) of 11.2 and 11.1 months in metastatic and locally advanced disease, respectively, from the date of trial enrollment, compared to ~4 - 6 months for metastatic patients and ~ 9 months for locally advanced patients with second-line chemotherapy, based on published historical data

✅ Favorable safety profile observed across the Alpha DaRT trials, with treatment-associated adverse events reported in 36% of subjects and Grade ≥3 events in 9%, with no treatment-related deaths and no chronic toxicity; all Grade ≥3 events resolved

✅ Following these strong survival data, Company next turns to anticipated completion of recruitment in the multicenter U.S. IMPACT pancreatic cancer trial, which is exploring the ability of Alpha DaRT, in combination with initiation of front-line chemotherapy, to deliver a potent and focused local dose without exacerbating the harsh systemic side effects of standard chemotherapy

For full PR - check the first comment

31/05/2026

Fox Business said it right: ASCO 2026 is the Super Bowl of oncology and Alpha Tau is the rising star in the game that is becoming impossible to ignore.

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update“The first quarter of 2026 has bee...
18/05/2026

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

“The first quarter of 2026 has been a truly defining period for Alpha Tau, reflecting the convergence of two powerful dynamics that have been years in the making: the maturation of clinical data from our most advanced programs, and the global initiation of novel trials addressing some of the most pressing unmet needs in oncology”.
𝑼𝒛𝒊 𝑺𝒐𝒇𝒆𝒓, 𝑪𝑬𝑶

For full press release - link in the first comment

Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Loc...
11/05/2026

Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET.

✅ Interim results from the first three brain cancer patients treated; two of whom demonstrated complete response, with total disappearance of all enhancing tumor lesions, per multiple MRI scans since treatment

✅ One associated grade 3 serious adverse event (SAE) was observed, since resolved

✅ According to the National Brain Tumor Society, glioblastoma is one of the most complex, deadly, and treatment-resistant cancers, with an estimated average survival rate of only 8 months -

✅ Conference call with principal investigator to be held today, Monday, May 11, 2026, at 8:30am ET

To read full PR - check the first comment

Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastom...
08/05/2026

Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma

For full PR check the first comment

Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of ...
08/05/2026

Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma

⭐ First U.S. pivotal study for Alpha Tau to have completed enrollment, representing a critical milestone on the path towards potential FDA pre-market approval (PMA); Company has already initiated PMA modular application process

⭐ Enrollment of all 88 patients completed in the ReSTART trial, a U.S. multicenter pivotal study evaluating Alpha DaRT® for the treatment of recurrent cutaneous squamous cell carcinoma (cSCC), for which the Alpha DaRT has received Breakthrough Device Designation from the FDA

⭐ ReSTART pivotal study builds on a foundation of clinical data from skin cancer studies conducted in Israel, Italy, France and the U.S.

⭐ - cSCC is the second most common form of skin cancer, with a rising incidence and a significant unmet need for patients who have exhausted surgical and conventional treatment options

Check the full PR in the first comment

Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Italy with Alpha DaRT® at the University of Verona’s Pa...
07/05/2026

Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Italy with Alpha DaRT® at the University of Verona’s Pancreas Institute

❇️ First patient ever treated with Alpha DaRT for pancreatic cancer in Italy, under a clinical study conducted at the world-renowned Pancreas Institute of the University of Verona

❇️ The study is the first Alpha DaRT pancreatic cancer protocol worldwide to permit both endoscopic ultrasound (EUS)-guided and percutaneous delivery of Alpha DaRT sources, expanding the spectrum of access alternatives available to physicians including interventional radiologists, interventional oncologists, gastroenterologists, endoscopists and surgeons

❇️ The successful treatment follows the first European patient treated in April 2026 in France’s ongoing multicenter ACAPELLA trial, and joins the ongoing IMPACT multicenter trial in the United States, reflecting the rapid global expansion of Alpha Tau’s pancreatic cancer program

❇️ According to the WHO (2022) 15,710 Italians were diagnosed with pancreatic cancer, while annual pancreatic cancer deaths reach 14,903- one of the very few common cancers in Italy where mortality remains high

For full PR - check the first comment

Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Canc...
04/05/2026

Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026

🟢100% local disease control rate achieved in evaluable patients in pooled analysis of two first-in-human trials of Alpha DaRT® in pancreatic adenocarcinoma

🟢Favorable safety profile observed, with only 8 device-associated adverse events in 7 of 26 subjects (27%), nearly all resolving within two weeks in some of the most challenging, heavily pre-treated patients in oncology

🟢Highly heterogeneous patient population for whom available options are extremely limited included patients ineligible for chemotherapy as well as patients who had received up to four prior lines of chemotherapy

🟢Streamlined outpatient endoscopic ultrasound (EUS)-guided procedure designed for seamless integration into standard GI endoscopy workflow

🟢Results shared in oral presentation at DDW 2026, the first presentation of Alpha DaRT at a premier international gastroenterology conference

For fill press release - check the first comment

Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer...
23/04/2026

Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)

▶️ IDE supplement expands trial to the other primary standard-of-care chemotherapy for pancreatic cancer patients, alongside mFOLFIRINOX

▶️ IDE supplement also expands total trial size from 30 to 40 patients

▶️ Study explores Alpha DaRT combined with chemotherapy in patients with newly diagnosed unresectable locally advanced or metastatic pancreatic adenocarcinoma

▶️ This pilot study is a key part of Alpha Tau’s broader strategy to bring Alpha DaRT to cancer patients with some of the highest unmet needs

Address

Kiryat Hamada 5
Jerusalem
9777605

Opening Hours

Monday 09:00 - 19:00
Tuesday 09:00 - 19:00
Wednesday 09:00 - 19:00
Thursday 09:00 - 19:00
Sunday 09:00 - 19:00

Telephone

+972586821373

Website

Alerts

Be the first to know and let us send you an email when Alpha Tau Medical posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Alpha Tau Medical:

Shortcuts

Share

Category